All In Biotech

Drug Trial Radar · NCT05364684

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study

Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

12

Actual

Start

Aug 10, 2022

Primary completion

Nov 22, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1H-MRS).

Conditions

  • NAFLD
  • Nonalcoholic Fatty Liver
  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • LUM-201Drug

    LUM-201 (ibutamoren mesylate) is an oral growth hormone secretagogue.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intrahepatic Lipid Content (IHL, Percent Liver Fat)Time frame: 6 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.